Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Neuromuscular Blockade in Infants
NCT03909165Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Primary completion
- Sep 2023
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 14
01
Overview
A Phase 4 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Jul 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03909165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909165.